이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Tianda Pharmaceuticals 관리

관리 기준 확인 3/4

Tianda Pharmaceuticals' CEO는 Alan Fang, Feb2017 에 임명되었습니다 의 임기는 7.33 년입니다. 는 HK$ 292.70M 가치에 해당하는 회사 주식의 56.72% 직접 소유합니다. 292.70M. 경영진과 이사회의 평균 재임 기간은 각각 7.3 년과 10.8 년입니다.

주요 정보

Alan Fang

최고 경영자

HK$60.0k

총 보상

CEO 급여 비율	n/a
CEO 임기	7.4yrs
CEO 소유권	56.7%
경영진 평균 재임 기간	7.4yrs
이사회 평균 재임 기간	10.8yrs

최근 관리 업데이트

Recent updates

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Jun 20

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Mar 27

CEO

Alan Fang (55 yo)

7.4yrs

테뉴어

HK$60,000

보상

Mr. Wen Quan Fang, also known as Alan, has been serves as Managing Director of Tianda Pharmaceuticals Limited since February 1, 2017. Mr. Fang has been Managing Director of Tianda Holdings Limited since Se...

리더십 팀

이름	위치	테뉴어	보상	소유권
Wen Quan Fang	Executive Chairman & MD	7.4yrs	HK$60.00k	56.72% HK$ 317.1m
Man Sang Lui	Executive Director	10.8yrs	HK$72.00k	데이터 없음
Man Yuk Wong	Financial Controller	4.5yrs	데이터 없음	데이터 없음
Tai On Lo	Company Secretary	no data	데이터 없음	데이터 없음

7.4yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: 455 의 관리팀은 노련하고 경험 (평균 재직 기간 7.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Wen Quan Fang	Executive Chairman & MD	20.8yrs	HK$60.00k	56.72% HK$ 317.1m
Man Sang Lui	Executive Director	10.8yrs	HK$72.00k	데이터 없음
Sung Hong Chiu	Independent Non-Executive Director	16.3yrs	HK$72.00k	데이터 없음
Yat-Fai Lam	Independent Non-Executive Director	19.8yrs	HK$72.00k	데이터 없음
Tao Zhong	Non-Executive Director	less than a year	HK$25.00k	데이터 없음
Quanming Feng	Non-Executive Director	8.3yrs	데이터 없음	데이터 없음
Yanfang Xian	Independent Non-executive Director	1.1yrs	HK$37.00k	데이터 없음

10.8yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 이사회: 455 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.8 년).

Tianda Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 07, 2024

Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023

Tianda Pharmaceuticals Limited Announces Board Changes

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2023

Executive Chairman & MD recently bought HK$2.7m worth of stock

Executive Chairman & MD recently bought HK$448k worth of stock

Recent updates

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd. Receives Drug Registration Approval of Ibuprofen Suspension

Tianda Pharmaceuticals Limited Approves Final Dividend

Now 24% overvalued after recent price rise

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 07, 2024

Now 21% overvalued after recent price rise

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

New major risk - Revenue and earnings growth

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023

Tianda Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Now 26% undervalued

Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Now 29% undervalued

Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Interim Period Ended June 30, 2023

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 28% undervalued

Tianda Pharmaceuticals Limited (SEHK:455) entered into an equity transfer agreement to acquire 45% stake in Yunnan Mengsheng Pharmaceutical Co., Ltd from Yunnan Linuo Biotechnology Co., Ltd. for HKD 23.5 million.

Tianda Pharmaceuticals Limited Announces Board Changes

Now 25% undervalued after recent price drop

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2023

Full year 2022 earnings released: HK$0.025 loss per share (vs HK$0.011 loss in FY 2021)

Executive Chairman & MD recently bought HK$2.7m worth of stock

Executive Chairman & MD recently bought HK$448k worth of stock

Executive Chairman & MD recently bought HK$52k worth of stock

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

First half 2023 earnings released: HK$0.008 loss per share (vs HK$0.008 loss in 1H 2022)

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 25, 2022

Less than half of directors are independent

Executive Chairman & MD recently bought HK$129k worth of stock

Tianda Pharmaceuticals Limited Declares Final Dividend

Tianda Pharmaceuticals Limited, Annual General Meeting, Aug 25, 2022

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended March 31, 2022, Payable on September 08, 2022

Full year 2022 earnings released

Tianda Pharmaceuticals Limited Proposes Special Dividend for the Year Ended 31 March 2022

Tianda Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Non-Executive Director Lee George Lam has left the company

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ended 31 March 2021

First half 2021 earnings released: HK$0.007 loss per share

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

First half 2021 earnings released: HK$0.007 loss per share

Tianda Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 27, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령